+

DK1200583T3 - Fremstilling af beta-foldeblad-proteiner med specifikke bindingsegenskaber - Google Patents

Fremstilling af beta-foldeblad-proteiner med specifikke bindingsegenskaber

Info

Publication number
DK1200583T3
DK1200583T3 DK00944034T DK00944034T DK1200583T3 DK 1200583 T3 DK1200583 T3 DK 1200583T3 DK 00944034 T DK00944034 T DK 00944034T DK 00944034 T DK00944034 T DK 00944034T DK 1200583 T3 DK1200583 T3 DK 1200583T3
Authority
DK
Denmark
Prior art keywords
specific binding
beta
preparation
binding properties
fold sheet
Prior art date
Application number
DK00944034T
Other languages
English (en)
Inventor
Ulrike Fiedler
Rainer Rudolph
Original Assignee
Scil Proteins Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scil Proteins Gmbh filed Critical Scil Proteins Gmbh
Application granted granted Critical
Publication of DK1200583T3 publication Critical patent/DK1200583T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
  • Laminated Bodies (AREA)
  • Wrappers (AREA)
DK00944034T 1999-07-13 2000-07-13 Fremstilling af beta-foldeblad-proteiner med specifikke bindingsegenskaber DK1200583T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19932688A DE19932688B4 (de) 1999-07-13 1999-07-13 Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
PCT/EP2000/006698 WO2001004144A2 (de) 1999-07-13 2000-07-13 Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften

Publications (1)

Publication Number Publication Date
DK1200583T3 true DK1200583T3 (da) 2007-02-19

Family

ID=7914599

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00944034T DK1200583T3 (da) 1999-07-13 2000-07-13 Fremstilling af beta-foldeblad-proteiner med specifikke bindingsegenskaber

Country Status (12)

Country Link
US (2) US7601803B1 (da)
EP (2) EP1780279A1 (da)
JP (2) JP4221174B2 (da)
CN (2) CN1371415A (da)
AT (1) ATE342359T1 (da)
AU (1) AU5827800A (da)
CA (1) CA2378871C (da)
DE (2) DE19932688B4 (da)
DK (1) DK1200583T3 (da)
ES (1) ES2273705T3 (da)
PT (1) PT1200583E (da)
WO (1) WO2001004144A2 (da)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932688B4 (de) * 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
DE10324447A1 (de) * 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
EA013615B1 (ru) 2004-11-12 2010-06-30 Байер Шеринг Фарма Акциенгезельшафт Рекомбинантный онколитический парамиксовирус и его применение
US20090054252A1 (en) 2005-01-03 2009-02-26 Martin Lanzendoerfer Hemopexin-Like Structure as New Polypeptide-Scaffold
US7611847B2 (en) 2005-06-01 2009-11-03 Agency For Science, Technology And Research Method for identifying an intestinal phenotype
WO2007061684A1 (en) 2005-11-18 2007-05-31 Board Of Regents, The University Of Texas System Quantification of fusion proteins and their activity from chromosomal translocation
BRPI0621413A2 (pt) 2006-02-13 2011-12-06 Agency Science Tech & Res método de processamento de uma amostra biológica e/ou quìmica
EP2004328B1 (en) 2006-03-09 2014-06-04 Agency for Science, Technology and Research Method for performing a reaction in a droplet
JP2009539346A (ja) 2006-05-26 2009-11-19 ワイカトリンク リミテッド Ｏｂフォールドドメイン
EP1862803A1 (en) 2006-06-02 2007-12-05 Atlas Antibodies AB Use of protein SATB2 as a marker for colorectal cancer
EP1925664A1 (en) * 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
WO2008063135A1 (en) 2006-11-24 2008-05-29 Agency For Science, Technology And Research Apparatus for processing a sample in a liquid droplet and method of using the same
US9874501B2 (en) 2006-11-24 2018-01-23 Curiox Biosystems Pte Ltd. Use of chemically patterned substrate for liquid handling, chemical and biological reactions
JP2010523652A (ja) 2007-04-13 2010-07-15 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 腫瘍発生を制御する方法および腫瘍発生のリスクを診断する方法
WO2008136769A1 (en) * 2007-05-03 2008-11-13 Nanyang Technological University Online contaminant detection and removal system
SG150405A1 (en) 2007-08-29 2009-03-30 Agency Science Tech & Res Method of coating a particle
DK2207809T3 (da) 2007-09-26 2013-10-07 U3 Pharma Gmbh Heparinbindende epidermal vækstfaktorlignende vækstfaktor-antigenbindende proteiner
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
US10725020B2 (en) 2007-11-14 2020-07-28 Curiox Biosystems Pte Ltd. High throughput miniaturized assay system and methods
WO2013114217A1 (en) 2012-02-05 2013-08-08 Curiox Biosystems Pte Ltd. Array plates and methods for making and using same
JP2011504960A (ja) * 2007-11-28 2011-02-17 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ Ｓｕ−８層を含む面を少なくとも１つ有する基板の低温接合方法
DE202008000834U1 (de) 2008-01-21 2008-05-29 Chin, Li-Te Zusammensetzung und Reagenz für CTLA-4 und Verwendungen derselben
EP2085092A1 (en) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
EP2090890A1 (en) 2008-02-15 2009-08-19 Atlas Antibodies AB RBM3 as a marker for breast cancer prognosis
US9102920B2 (en) 2008-05-06 2015-08-11 Agency For Science, Technology And Research Method of effecting de-differentiation of a cell
WO2010086400A1 (en) 2009-01-30 2010-08-05 Atlas Antibodies Ab Combination treatment of breast cancer
WO2009138130A1 (en) 2008-05-16 2009-11-19 Atlas Antibodies Ab Breast cancer prognostics
AR072897A1 (es) 2008-08-05 2010-09-29 Novartis Ag Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
WO2010016800A1 (en) 2008-08-08 2010-02-11 Agency For Science, Technology And Research Microfluidic continuous flow device
EP2161577A1 (en) 2008-09-01 2010-03-10 Atlas Antibodies AB ANLN protein
EP2172477A1 (en) 2008-10-06 2010-04-07 Atlas Antibodies AB Epitopes derived from SATB2 and uses thereof
US8716420B2 (en) 2008-10-13 2014-05-06 Agency For Science, Technology And Research Amphiphilic polymers and nanocrystals coated therewith
CA2746840A1 (en) 2008-12-16 2010-06-24 Novartis Ag Yeast display systems
EP2293070A1 (en) 2009-08-13 2011-03-09 Atlas Antibodies AB Means and methods for ovarian cancer prognosis
EP2241889A1 (en) 2009-04-16 2010-10-20 Atlas Antibodies AB RBM3 protein in colorectal cancer prognostics
EP2524928A1 (en) 2011-05-18 2012-11-21 Atlas Antibodies AB RBM3 in bladder cancer
EP2396657B1 (en) 2009-02-16 2013-11-13 Atlas Antibodies AB Rbm3 as a marker for malignant melanoma prognosis
WO2010112458A1 (en) 2009-03-31 2010-10-07 Novartis Ag Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit
US8784752B2 (en) 2009-04-17 2014-07-22 Curiox Biosystems Pte Ltd Use of chemically patterned substrate for liquid handling, chemical and biological reactions
CA2758290C (en) 2009-04-27 2018-04-10 Novartis Ag Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
EP2259059A1 (en) 2009-05-29 2010-12-08 Atlas Antibodies AB Means and methods for ovarian cancer prognosis
CN102549427A (zh) 2009-07-07 2012-07-04 新加坡科技研究局 鉴定结合配偶体对的方法
EP2464657B1 (en) 2009-08-10 2015-04-01 MorphoSys AG Novel screening strategies for the identification of antibodies or fragments thereof which bind an antigen that has an enzymatic activity
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
EP2488548A1 (en) 2009-10-14 2012-08-22 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung A low density lipoprotein-related protein 1 splice variant as cancer marker
EP2315028A1 (en) 2009-10-26 2011-04-27 Atlas Antibodies AB PODXL protein in colorectal cancer
WO2011080050A2 (en) 2009-12-11 2011-07-07 Novartis Ag Binding molecules
CN102753568B (zh) 2009-12-14 2014-08-20 塞尔蛋白质股份有限公司 用于识别具有结合配体能力的异源多聚体修饰的泛素蛋白质的方法
ES2574056T3 (es) 2010-03-31 2016-06-14 Agency For Science, Technology And Research Péptido/peptoide anfifílico lineal e hidrogel que comprende el mismo
ES2659406T3 (es) 2010-05-06 2018-03-15 Novartis Ag Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
WO2011138391A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EP2390665A1 (en) 2010-05-27 2011-11-30 Atlas Antibodies AB Prostate cancer biomarkers
US9878328B2 (en) 2010-07-23 2018-01-30 Curiox Biosystems Pte Ltd. Apparatus and method for multiple reactions in small volumes
SG187908A1 (en) 2010-08-20 2013-03-28 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
JP2013543384A (ja) 2010-10-05 2013-12-05 ノバルティス アーゲー 抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
JP6057904B2 (ja) 2010-10-27 2017-01-11 スパイバー テクノロジーズ アーベーＳｐｉｂｅｒ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ａｂ 有機ターゲットに結合するためのクモ糸融合タンパク質構造
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
AU2012268970B2 (en) 2011-06-15 2016-01-28 Navigo Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
PT2726099T (pt) 2011-07-01 2018-11-13 Novartis Ag Método para o tratamento de distúrbios metabólicos
EP2544007A1 (en) 2011-07-07 2013-01-09 Atlas Antibodies AB Biomarker of renal impairment
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
EP2573566A1 (en) 2011-09-20 2013-03-27 Atlas Antibodies AB RBM3 in prostate cancer prognostics
MX2014004319A (es) 2011-10-17 2015-05-15 Univ Muenster Wilhelms Valoracion del riesgo de pml (leucoencefalopatia multifocal progresiva) y metodos basados en la misma.
CN104159924B (zh) 2011-12-05 2018-03-16 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
TW201328707A (zh) 2011-12-05 2013-07-16 Novartis Ag 針對表皮生長因子受體３（ｈｅｒ３）之區域ｉｉ之ｈｅｒ３抗體
EP2602622A1 (en) 2011-12-07 2013-06-12 Atlas Antibodies AB Prediction of response to platinum-based therapy
WO2013093762A1 (en) 2011-12-21 2013-06-27 Novartis Ag Compositions and methods for antibodies targeting factor p
WO2013098676A1 (en) 2011-12-30 2013-07-04 Grifols, S.A. Method for purifying factor viii
WO2013124474A2 (en) 2012-02-23 2013-08-29 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
ES2529018T3 (es) 2012-04-02 2015-02-16 F. Hoffmann-La Roche Ag Métodos y uso para la evaluación de la gravedad de la enfermedad pulmonar obstructiva crónica (EPOC)
JP6412866B2 (ja) 2012-05-02 2018-10-24 スパイバー テクノロジーズ アーベーＳｐｉｂｅｒ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ａｂ 有機ターゲットに結合するための反復断片を持たないクモ糸融合タンパク質の構造
WO2013189521A1 (en) 2012-06-19 2013-12-27 Waclawczyk Simon Method of generating cells of hepatocyte phenotype
EP2687850A1 (en) 2012-07-19 2014-01-22 Roche Diagniostics GmbH Methods of stratifying for respiratory support therapy
SG11201501382YA (en) 2012-08-27 2015-03-30 Univ Nanyang Tech Nanoparticulate contrast agent
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
CA2884151A1 (en) 2012-09-10 2014-03-13 Westfaelische Wilhelms-Universitaet Muenster Methods and compounds for preventing, treating and diagnosing an inflammatory condition
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
CN104968678B (zh) 2012-12-05 2018-12-11 诺华股份有限公司 靶向epo的抗体的组合物和方法
EP2746768A1 (en) 2012-12-20 2014-06-25 Atlas Antibodies AB Podxl in bladder cancer
WO2014122613A1 (en) 2013-02-08 2014-08-14 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
US9944700B2 (en) 2013-03-13 2018-04-17 Novartis Ag Notch2 binding molecules for treating respiratory diseases
JP2016514130A (ja) 2013-03-14 2016-05-19 ノバルティス アーゲー Ｎｏｔｃｈ３に対する抗体
US20160030603A1 (en) 2013-03-15 2016-02-04 Westfaelische Wilhelms-Universitaet Muenster Detection of acute renal allograft rejection
EP2787350A1 (en) 2013-04-05 2014-10-08 Atlas Antibodies AB ASRGL1 in endometrial cancer
UY35620A (es) 2013-06-21 2015-01-30 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US9557318B2 (en) 2013-07-09 2017-01-31 Curiox Biosystems Pte Ltd. Array plates for washing samples
DK3024485T3 (da) 2013-07-23 2020-12-07 Biocon Ltd Anvendelse af en CD6-bindingspartner og fremgangsmåde baseret derpå
BR112016002198A2 (pt) 2013-08-14 2017-09-12 Novartis Ag métodos de tratamento de miosite por corpos de inclusão esporádica
WO2015069459A1 (en) 2013-11-05 2015-05-14 Novartis Ag Organic compounds
WO2015078711A2 (en) 2013-11-18 2015-06-04 Westfaelische Wilhelms-Universitaet Muenster Methods, peptides and antibodies for preventing, treating and diagnosing an inflammatory condition
LU92409B1 (en) 2014-03-21 2015-09-22 Philipps Universit T Marburg Means and methods for itaconic acid production
CN116656605A (zh) 2014-04-16 2023-08-29 朱诺治疗有限公司 用于扩增细胞群的方法、试剂盒及装置
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
AU2015254588B2 (en) 2014-04-30 2020-05-21 Iba Gmbh Method of isolating a target cell
CN104059119A (zh) * 2014-06-10 2014-09-24 高海岗 雌二醇半抗原、抗原、抗体及其制备方法与应用
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
EP3194437B1 (en) 2014-08-07 2021-01-20 Novartis AG Angiopoietin-like 4 (angptl4) antibodies and methods of use
KR20240056627A (ko) 2014-08-07 2024-04-30 노파르티스 아게 안지오포이에틴-유사 4 항체 및 사용 방법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3023791A1 (en) 2014-11-21 2016-05-25 Atlas Antibodies AB Predicting the responsiveness to gemcitabine treatment
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
CA2975362A1 (en) 2015-02-06 2016-08-11 Navigo Proteins Gmbh Egfr binding proteins comprising ubiquitin muteins
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
EA201792561A1 (ru) 2015-06-05 2018-04-30 Новартис Аг Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
US10545139B2 (en) 2015-06-16 2020-01-28 Curiox Biosystems Pte Ltd. Methods and devices for performing biological assays using magnetic components
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
DK3322721T3 (da) 2015-07-16 2022-03-14 Navigo Proteins Gmbh Nye immunglobulin-bindende proteiner og deres anvendelse i affinitetsoprensning
CA2991815A1 (en) 2015-07-20 2017-01-26 Navigo Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
CN108350072B (zh) 2015-08-03 2022-05-24 诺华股份有限公司 治疗fgf21相关病症的方法
UY36889A (es) 2015-09-09 2017-04-28 Novartis Ag Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CU24533B1 (es) 2015-09-09 2021-07-02 Novartis Ag Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
CN116875635A (zh) 2015-10-22 2023-10-13 朱诺治疗学有限公司 用于转导的方法、反应剂盒、反应剂和设备
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
JP2019506844A (ja) 2015-12-18 2019-03-14 ノバルティス アーゲー ＣＤ３２ｂを標的とする抗体およびその使用方法
JP7138567B2 (ja) 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子１５に対する抗体およびそれらの使用
EP3452097A1 (en) 2016-05-04 2019-03-13 Navigo Proteins GmbH Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
CN110381988A (zh) 2016-06-15 2019-10-25 诺华股份有限公司 使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法
CN116333065A (zh) 2016-08-11 2023-06-27 纳维格蛋白质有限公司 新型对碱稳定的免疫球蛋白结合蛋白
CA3048156A1 (en) 2016-12-23 2018-06-28 Novartis Ag Factor xi antibodies and methods of use
CA3052911A1 (en) 2017-02-08 2018-08-16 Novartis Ag Fgf21 mimetic antibodies and uses thereof
KR20240014600A (ko) 2017-03-24 2024-02-01 노바르티스 아게 심장질환 예방 및 치료 방법
EP3607580B1 (en) 2017-04-05 2023-05-31 Curiox Biosystems Pte Ltd. Methods, devices, and apparatus for washing samples on array plates
IL270142B2 (en) 2017-04-27 2025-05-01 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of using them
US20210156844A1 (en) 2017-05-02 2021-05-27 Bayer Aktiengesellschaft TMEM16A Modulation for Diagnostic or Therapeutic Use in Pulmonary Hypertension (PH)
CN107163261B (zh) * 2017-05-04 2019-12-06 苏州大学 一种丝素蛋白乳状液滴及其制备方法
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2019003104A1 (en) 2017-06-28 2019-01-03 Novartis Ag METHOD FOR PREVENTING AND TREATING URINARY INCONTINENCE
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
EP3704153A2 (en) 2017-11-02 2020-09-09 Bayer Aktiengesellschaft Bispecific antibodies binding alk-1 and bmpr-2
US11414466B2 (en) 2017-11-07 2022-08-16 Navigo Proteins Gmbh Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
WO2019102353A1 (en) 2017-11-22 2019-05-31 Novartis Ag Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US11845797B2 (en) 2018-07-03 2023-12-19 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2020043693A1 (en) 2018-08-29 2020-03-05 Westfälische Wilhelms-Universität Münster Diagnosis of multiple sclerosis
DE102018124022A1 (de) 2018-09-28 2020-04-02 Rheinisch-Westfälische Technische Hochschule (Rwth) Aachen Hyaluronsäurestabilisator
CA3117568A1 (en) 2018-10-31 2020-05-07 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
US20220025070A1 (en) 2018-12-18 2022-01-27 Novartis Ag Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
EP3998081A4 (en) 2019-07-05 2023-07-12 Ono Pharmaceutical Co., Ltd. TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN
TW202120550A (zh) 2019-08-08 2021-06-01 日商小野藥品工業股份有限公司 雙特異性蛋白質
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
US11802141B2 (en) 2019-10-25 2023-10-31 University Of Washington De novo designed non-local beta sheet proteins
BR112022008023A2 (pt) 2019-10-30 2022-07-12 Juno Therapeutics Gmbh Dispositivos de seleção e/ou estimulação de células e métodos de uso
JP7502451B2 (ja) 2020-01-31 2024-06-18 セル．コペディア ゲーエムベーハー 生物学的実体を単離する方法
WO2022157094A2 (en) 2021-01-22 2022-07-28 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof
WO2022207748A1 (en) 2021-03-30 2022-10-06 Westfälische Wilhelms-Universität Münster Classification of neurological or psychiatric disease manifestations using multi-dimensional cerebrospinal fluid analysis
CN117597359A (zh) 2021-04-08 2024-02-23 马伦戈治疗公司 与tcr结合的多功能分子及其用途
EP4334341A2 (en) 2021-05-06 2024-03-13 Juno Therapeutics GmbH Methods for stimulating and transducing t cells
WO2023017115A1 (en) 2021-08-11 2023-02-16 Iba Lifesciences Gmbh Fractionation of cells based on a marker protein
WO2023217904A1 (en) 2022-05-10 2023-11-16 Institut National de la Santé et de la Recherche Médicale Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
EP4379375A1 (en) 2022-12-01 2024-06-05 Universität Münster Classification of connective tissue disease with neurological manifestation using multi-dimensional peripheral blood analysis
WO2024200655A1 (en) 2023-03-28 2024-10-03 Westfälische Wilhelms-Universität Münster Predictive level of pd-l1 on microvesicles in the evaluation whether being a responder to a treatment of nsclc
WO2025008404A1 (en) 2023-07-04 2025-01-09 Universitaet Regensburg In Vertretung Des Freistaates Bayern Use of soluble cd46 concentration from peripheral blood as a parameter for the diagnosis of non-alcoholic fatty liver disease
WO2025040598A2 (en) 2023-08-18 2025-02-27 Immatics Biotechnologies Gmbh Peptides displayed by mhc for use in immunotherapy against different types of cancer

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) * 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
AU7142796A (en) * 1995-10-02 1997-04-28 Erasmus University Rotterdam Diagnosis method and reagents
US6217863B1 (en) 1995-10-30 2001-04-17 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase I
US5789166A (en) * 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
FR2761688A1 (fr) * 1997-04-02 1998-10-09 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
FR2761689B1 (fr) 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
DK0985032T4 (da) * 1997-05-28 2009-08-31 Crescendo Biolog Ltd Ribosom-komplekser som selektionspartikler til in vitro fremvisning og evolution af proteiner
US6673901B2 (en) * 1997-06-12 2004-01-06 Research Corporation Technologies, Inc. Artificial antibody polypeptides
DE19742706B4 (de) * 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
EP1257297B1 (en) 2000-02-24 2006-07-26 Philogen S.p.A. Compositions and methods for treatemnt of angiogenesis in pathological lesions
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US6799121B2 (en) * 2000-03-30 2004-09-28 York University Sequencing of peptides by mass spectrometry
US20040043386A1 (en) * 2002-08-30 2004-03-04 Todd Pray Methods and compositions for functional ubiquitin assays
DE10324447A1 (de) * 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
WO2005044845A2 (en) 2003-11-04 2005-05-19 Yale University Protein binding miniature proteins
US7393918B2 (en) 2003-12-11 2008-07-01 Yale University Protein binding miniature proteins and uses thereof
DE102004049479A1 (de) * 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
BRPI0609100A2 (pt) 2005-05-11 2010-02-17 Philogen Spa conjugado para alvejamento de fármaco, método de produzir o referido conjugado, bem como composição contendo o mesmo
WO2007054120A1 (de) 2005-11-09 2007-05-18 Bayer Schering Pharma Aktiengesellschaft Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
EP1842553A1 (en) 2006-04-07 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
MX2008013575A (es) 2006-05-08 2008-11-04 Philogen Spa Citoquinas dirigidas a anticuerpos para terapia.
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
EP1955712A1 (en) 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
CN102753568B (zh) 2009-12-14 2014-08-20 塞尔蛋白质股份有限公司 用于识别具有结合配体能力的异源多聚体修饰的泛素蛋白质的方法

Also Published As

Publication number Publication date
ATE342359T1 (de) 2006-11-15
ES2273705T3 (es) 2007-05-16
US7601803B1 (en) 2009-10-13
CN1371415A (zh) 2002-09-25
EP1200583B1 (de) 2006-10-11
JP2003504081A (ja) 2003-02-04
EP1200583A2 (de) 2002-05-02
CA2378871C (en) 2012-04-17
WO2001004144A3 (de) 2001-08-02
EP1780279A1 (de) 2007-05-02
JP4597177B2 (ja) 2010-12-15
JP4221174B2 (ja) 2009-02-12
CA2378871A1 (en) 2001-01-18
AU5827800A (en) 2001-01-30
US20070111287A1 (en) 2007-05-17
JP2008019276A (ja) 2008-01-31
US8592144B2 (en) 2013-11-26
WO2001004144A2 (de) 2001-01-18
DE50013610D1 (de) 2006-11-23
DE19932688A1 (de) 2001-01-18
CN101693889A (zh) 2010-04-14
PT1200583E (pt) 2006-12-29
DE19932688B4 (de) 2009-10-08

Similar Documents

Publication Publication Date Title
DK1200583T3 (da) Fremstilling af beta-foldeblad-proteiner med specifikke bindingsegenskaber
DE502004012225D1 (de) Generierung künstlicher bindungsproteine auf der grundlage von ubiquitin-proteinen
CY1113153T1 (el) ΙL-1β ΔΕΣΜΕΥΤΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΚΑΙ ΘΡΑΥΣΜΑΤΑ ΑΥΤΩΝ
BR9914374A (pt) Sequências genÈmicas de neisseria e métodos para seu uso
EP1862472A3 (en) Chlamydia protein, gene sequence and uses thereof
EP2277889A3 (en) Fusion proteins of albumin and interferon beta
EP2330129A3 (en) Anti-TNF antibodies, compositions, methods and uses
CY1106806T1 (el) Dna και πολυπεπτιδια ανθρωπινης tslp
EP2330197A3 (en) Antagonistic selective binding agents of osteoprotegerin binding protein
EP1832599A3 (en) Albumin fusion proteins
WO2003020932A1 (fr) Nouvelles proteines de secretion et adn associe
AU4981101A (en) Subtilisin variants
WO2001012659A3 (en) Human dna sequences
AU3075995A (en) Process for modifying the stability of antibodies
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
BR0213774A (pt) Molécula de ácido nucleio isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina
AU1239997A (en) Polypeptides corresponding to the amino acid sequences of proteins p57 or p9.5 of Borna disease virus, nucleic acid fragments coding therefore and their use for diagnostic and immunization purposes
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
DE69737476D1 (de) Neuer galaninrezeptor
AUPM772494A0 (en) Improvements in production of proteins in host cells
ATE346919T1 (de) Nebenhoden-spezifisches rezeptorprotein und dessen verwendung
WO2002062964A3 (en) Ap1 amine oxidase variants
DK1208213T3 (da) Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner
WO2003104449A3 (en) IMPROVEMENTS IN PROTEIN PRODUCTION
EP1456382A4 (en) GLYCOSYLATION RESISTANT CYANOVIRINS AND CONJUGATES, COMPOSITIONS, NUCLEIC ACIDS, VECTORS, HOST, ASSOCIATED CELLS, AND METHODS OF OBTAINING AND USING NON-GLYCOSYLATED CYANOVIRINS
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载